Mecbotamab vedotin is under clinical development by BioAtla and currently in Phase II for Liver Cancer. According to GlobalData, Phase II drugs for Liver Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mecbotamab vedotin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mecbotamab vedotin overview

BA-3011 is under development for the treatment of solid tumors include non-squamous non-small cell lung cancer (NSCLC), oral cancer, castration-resistant prostate cancer (CRPC), bladder cancer, breast cancer, fallopian tube cancer and peritoneal cancer, colorectal cancer, oral cancer, cervical cancer, ovarian cancer, head and neck cancer, liver cancer, lung cancer, melanoma, stomach cancer, pancreatic cancer, soft tissue sarcoma, bone sarcoma, and endometrial cancer, chondrosarcoma, adenoid cystic carcinoma (ACC), renal cell carcinoma, mesothelioma of the pleura, leiomyosarcoma. The drug candidate acts by targeting AXL receptor tyrosine kinase. The drug candidate is developed based on  conditionally active biologics (CAB) platforms.

It was under development for Ewing sarcoma, osteosarcoma, synovial sarcoma, liposarcoma.

BioAtla overview

BioAtla is a clinical-stage biopharmaceutical company that develops novel therapies for the treatment of solid tumor cancer. The company product candidate includes BA3011, BA3021 and BA3071, BA3182, BA3142, BA3311, BA336 and BA3151. BioAtla lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate (ADC) that targets AXL, which is a protein kinase receptor. Its BA3021 is developing a CAB antibody-drug conjugate directed against receptor tyrosine kinase such as orphan receptor 2 (ROR2), BA3071 is therapeutic for multiple solid tumor indications, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer and cervical cancer. BioAtla is headquartered in San Diego, California, the US.

For a complete picture of Mecbotamab vedotin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.